Pharmafile Logo
Pharmafocus logo
Advanced Search

Mesoblast

Showing 5 posts of 5 posts found.

FDA defies advisory panel recommendation, rejecting Mesoblast’s Ryoncil in paediatric steroid-refractory acute graft versus host disease

October 5, 2020
Sales and Marketing FDA, Mesoblast, Ryoncil

The FDA has issued a surprising rejection of Mesoblast’s Ryoncil (remestemcel-L) as a treatment for paediatric steroid-refractory acute graft versus …

News
fda2outsideweb

FDA panel votes 9-1 in favour of approval for Mesoblast’s Ryoncil in paediatric steroid-refractory acute graft versus host disease

August 14, 2020
Medical Communications, Sales and Marketing FDA, Mesoblast, Ryoncil, pharma

It’s good news for Mesoblast as an expert FDA panel gave a glowing recommendation for the approval in the US …

News

Experimental stem cell treatment shows promise in rheumatoid arthritis

August 10, 2016
Research and Development Mesoblast, rheumatoid arthritis, stem cell treatment

Mesoblast has announced results from a Phase II clinical trial evaluating MPC-300-IV in patients with biologic refractory rheumatoid arthritis (RA) …

News
teva_copy

Teva returns rights to heart cell therapy to Mesoblast

June 16, 2016
Research and Development, Sales and Marketing Mesoblast, Teva, chronic heart failure, phase III

Israeli drugmaker Teva (NYSE: TEVA) has returned full rights to a drug for heart condition in late stage trials to …

News

Lonza signs regenerative medicine deal with Mesoblast

September 27, 2011
Manufacturing and Production Lonza, Mesoblast, pharma manufacturing news

Lonza has entered into a strategic-level alliance with Mesoblast, a specialist in regenerative medicines, which could see the construction of …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024